Semaglutide, a GLP-1 receptor mono-agonist, is in phase 3 development for noncirrhotic MASH, having demonstrated histological improvements in a phase 2 MASH trial6. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.